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Supplementary information  
 
Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding 
site.  






















































Reagents: (a) tert‐butyl 4‐bromobutylcarbamate, K2CO3, acetone; (b) CuI, sodium azide, L‐proline, NaOH,
DMSO; (c) NaOH, water, methanol; (d) 4‐(6,7‐dimethoxy‐3,4‐dihydroisoquinolin‐2(1H)‐yl)butan‐1‐amine,




Supplementary Figure S1.  Synthesis of the novel photoaffinity probe WC-21.  WC-21 was 
synthesized from compound 1, the methyl 2-hydroxy-5-iodobenzoate (1) and tert-butyl 4-
bromobutylcarbamate in acetone was heated to reflux with K2CO3 as a base to give compound 2, 
then the iodo of 2 was substituted with azido to afford 3. The methyl ester of 3 was hydrolyzed 
with NaOH in methanol and water, acidified with HCl (1:1) to give the acid 4, which was 
coupled with 4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butan-1-amine by using DCC 
and HOBt as coupling agents to afford 5. The N-Boc group of compound 5 was removed with 
TFA, and the free base reacted with fluorescein thioisocyanate (FITC) to give the final 
compound WC-21. 1H and 13C NMR spectrums of compounds 2, 3, 4, 5 and WC-21were shown 






Supplementary Figure S2.  Analytical HPLC chromatograph of WC-21.   The purity of WC-
































Supplementary Figure S3.  WC-21 ESI/Mass Spectrometry.  The molecular weight of WC-21 















Supplementary Figure S4.  Western blot analysis of the 24 kDa photoaffinity labeled 
protein; specific binding to sigma-2 receptors in hepatic membrane homogenates.   Hepatic 
membranes were photo cross-linked after incubation with WC-21 alone or together with the 
known, non-selective sigma-2 receptor ligands DTG and haloperidol or with a selective sigma-2 
compound RHM-1. Western blot with a HRP-conjugated anti-FITC antibody shows a single 
protein band (sigma-2 receptor), which can be blocked by sigma-2 receptor ligands. Molecular 































Supplementary Figure S5. Pharmacological profile of [125I]RHM-4 at sigma-2 receptors in 
mouse mammary 66 tumor cells.   Mouse mammary 66 tumor cell homogenates were 
incubated [125I]RHM-4 together with the PGRMC1 ligand AG-205, known sigma-2 receptor 
ligands DTG, WC-26, SV119, siramesine, or the sigma-1 receptor ligand (+)-pentazocine, 
[125I]RHM-4 binding was blocked by AG-205, DTG, WC-26, SV119 and siramesine, but the 
binding was not blocked by (+)-pentazocine. Data represents means ± SEM of %control specific 
















































Supplementary Figure S6. Correlation between the sigma-2 receptor binding and 
PGRMC1 expression levels in human HEK 293T cells.  HEK 293T cells were treated with 
PGRMC1-specific siRNA; a nontargetting scrambled siRNA was used as a control. a, 
Quantitative real-time RT-PCR was performed to assess downregulation of the target mRNA. b, 
cells treated with PGRMC1-specific siRNA showed a large reduction in binding of the 
fluorophore-containing sigma-2 ligand, SW120. Data represents one of the two replicates, 


























































Supplementary Figure S7. Sigma-1 receptor binding activity assayed using [3H](+)-
pentazocine in nontargeting siRNA and PGRMC1 siRNA treated cells; and in cells 
transfected with vector and PGRMC1 cDNA.   The bar graphs show that no significant 
changes in sigma-1 receptor binding activity were observed for the PGRMC1 specific siRNA 
treated (a) or the PGRMC1 cDNA transfected (b) HeLa cells relative to nontargeting siRNA 
treated or the vector transfected controls. Data represents means ± SEM of %control specific 







































Supplementary Figure S8.  Correlation between the sigma-2 receptor binding of 
[125I]RHM-4 and PGRMC1 protein expression in mouse mammary adenocarcinoma 66 and 
67 cells.  a, Typical Western blot of PGRMC1 protein expression in lysates of mouse mammary 
cancer cell lines 66 and 67 after 6 (proliferative cells), 12 (early quiescent cells) and 18 (late 
quiescent cells) days in culture; actin is the loading control. b, Correlation (R=0.88) between 
[125I]RHM-4 binding and the PGRMC1: actin ratio. Data represents means ± SEM [125I]RHM-4 


















Supplementary Figure S9. Intracellular localization of PGRMC1 labeled with a fluorescent 
anti-PGRMC1 antibody, and sigma-2 receptors labeled with SW120 in HeLa cells using 
confocal microscopy, high magnification images.   Sigma-2 receptors labeled with SW120 and 
PGRMC1 partially colocalized with mitochondria trackers/markers (a, b) and endoplasmic 
reticulum trackers/markers (c, d) in HeLa cells. For imaging sigma-2 receptors, live cells were 
incubated with SW120 and either MitoTracker Red CMXRos or ER-Tracker Red and then 
imaged by confocal microscopy. For imaging PRGMC1, cells were fixed and incubated with 
goat anti-PGRMC1 antibody followed by staining with Mito-marker (anti-COX IV antibody) or 
ER-marker (anti-GRP78 BiP antibody). Fluorescent labeled HeLa cells were then coverslipped 








































Supplementary Figure S19.  75 MHz 13C NMR (DMSO-d6) spectrum of compound WC-21. 
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Supplementary Table S1. PCR primers used for fragment amplification of PGRMC1. 






Receptor binding assay 
The receptor binding assay was performed with a filtration procedure as previously described 20. 
Competitive binding with [3H]RHM-1 was used to measure the sigma-2 receptor binding affinity 
of WC-21, RHM-4 and SW120 in rat liver membrane. [3H](+)-pentazocine was used to 
determine the sigma-1 receptor binding affinity of WC-21, RHM-4 and SW120 in guinea pig 
brain membrane (Figs. 1a, 2a inset, 4a). Briefly, rat liver (sigma-2 receptor assay) or guinea pig 
brain (sigma-1 receptor assay) membrane homogenates (~300 µg protein) were diluted with 50 
mM Tris-HCl, pH 8.0 and incubated with either 1 nM [3H]RHM-1 (80 Ci/mmol~5 nM; sigma-2 
receptor assay) or [3H](+)-pentazocine (34.9 Ci/mmol; sigma-1 receptor assay) in a total volume 
of 150 µL in 96 well plates at 25 °C. The concentrations of WC-21, RHM-4 and SW120 ranged 
from 0.1 nM to 10 µM. After incubation for 1 h, the reactions were terminated by the addition of 
150 µL of cold wash buffer (10 mM Tris-HCl, 150 mM NaCl, pH 7.4) using a 96 channel 
pipette, and the samples were harvested and filtered rapidly into a 96 well fiberglass filter plate 
(Millipore, Billerica, MA, USA) that had been presoaked with 200 µL of 50 mM Tris-HCl, at pH 
8.0 for 1 h. Each filter was washed three times with 200 µL of ice-cold wash buffer, and the 
bound radioactivity quantified using a Wallac 1450 MicroBeta liquid scintillation counter 
(Perkin Elmer, Boston, MA, USA). Nonspecific binding was determined from samples in the 
presence of 10 µM haloperidol.  
To determine the pharmacological profile of [125I]RHM-4 at sigma-2 receptors in the 
human HeLa and mouse mammary 66 cells, cell homogenates (~100 µg protein) were incubated 
with 0.5 nM of [125I]RHM-4 together with the PGRMC1 ligand AG-205 (10 µM), known sigma-
2 receptor ligands DTG (1 µM), WC-26 (100 nM), SV119 (100 nM), and siramesine (100 nM), 
or with the sigma-1 receptor ligand (+)-pentazocine (100 nM). The competitive [125I]RHM-4 
binding assay was carried out using the filtration procedure described above; the filters were 
punched out and the radioactivity of the bound protein on each filter was quantified via a 
Packard gamma counter (Perkin Elmer, Boston, MA, USA).  
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Direct binding assays were performed as above with 3.5 nM [125I]RHM-4 but without the 
competing ligands to determine the sigma-2 receptor binding activity in HeLa cell membranes 
(~100 µg protein) prepared from either PGRMC1 knockdown cells treated with PGRMC-1 
siRNA or from control cells treated with nontargeting siRNA. Direct binding assays were also 
performed for the PGRMC1 overexpressed HeLa cells treated with PGRMC1-cDNA and for 
vector treated control cells. The radioligand [3H](+)-pentazocine (8 nM) was used for binding 
assays to measure the sigma-1 receptor binding activity in those HeLa cells. 
 
Western blot analysis of PGRMC1 
Human HeLa and mouse mammary 66 tumor cells were lysed in radioimmunoprecipitation assay 
buffer [50 mM Tris, 150 mM sodium chloride, 1.0 mM EDTA, 1% Nonidet P40, and 0.25% SDS 
(pH 7.0)], supplemented with complete protease inhibitor cocktail (Roche, Mannheim, Germany) 
and phosphatase inhibitor cocktail 1 (Sigma Chemical Co., St. Louis, MO, USA). The cells were 
sonicated briefly, centrifuged at 13,000 × g for 20 min at 4 °C, and the supernatant collected. The 
protein concentration was determined using a Bio-Rad Dc protein assay kit (Bio-Rad 
Laboratories, Hercules, CA, USA). Lysates containing 30 µg of protein were run on a 12% 
acrylamide gel and transferred to a PVDF membrane (Bio-Rad Laboratories, Hercules, CA, 
USA). The PVDF membrane was incubated with 5% nonfat dry milk for 1 h at room 
temperature, then overnight with a rabbit anti-PGRMC1 antibody (1:600) at 4 °C, and finally 
with the secondary antibody, horseradish peroxidase-conjugated goat anti-rabbit IgG (Cell 
Signaling Technology, Danvers, MA, USA) at a 1:3,000 dilution. Actin was identified using an 
anti-β-actin antibody (Cell Signaling Technology, Danvers, MA, USA) at a 1:1,000 dilution and 
horseradish peroxidase-conjugated goat anti-rabbit IgG as the secondary antibody. The 
SuperSignal West Pico Chemiluminescent Substrate assay kit (Pierce Biotechnology, Inc. 
Rockford, IL, USA) was used to detect the secondary antibody. Quantitative analysis was 
performed using ImageJ software (National Institute of Health, USA), and the integrated 





Real time PCR for PGRMC1 mRNA expression 
HEK 293T cells were grown to 70-80% confluence in 6-well plates. 5 µL of the Fugene-6 
transfection reagent (Roche Diagnostics, Indianapolis, IN, USA) was mixed in 100 µL of Opti-
MEM. An appropriate amount of the siRNA (Dharmacon, Inc., Chicago, IL, USA) was 
combined with Opti-MEM to create a final concentration of 200 nM in 500 µL of Opti-MEM. 
After 72 h cells were treated with 50 nM of SW-120 for 30 min, assayed by flow cytometry 
(FACScan, BD Biosciences, San Jose, CA, USA), and the data analyzed with the CellQuest 
software (BD Biosciences, San Jose, CA, USA).  
 Real-time quantitative PCR was performed to validate mRNA expression knockdown. 
Total RNA was isolated using RNeasy Mini Kit (Qiagen, Valencia, CA, USA). The amount of 
RNA was measured by spectrophotometer. RNA (2 µg) was transcribed into cDNA using 
SupersScriptTM III (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s 
instructions. Real-time quantitative PCR was performed in triplicate with PGRMC1-specific 
primers (TaqMan® Gene Expression Assay, Hs00198499_m1, amplicon size 54; forward primer 
5’-ACCAAAGGCCGCAAATTC-3’, reverse primer 5’-TCCAGCAAAGACCCCATAC-3’, 
Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer’s directions. Fragment 
amplification was performed on an ABI PrismTM 7500 Sequence Detector. The expression of 
PGRMC1 was standardized relative to the expression of β-Actin. 
 
Synthesis of the novel photoaffinity probe WC-21 
All chemicals were obtained from standard commercial sources and used without further 
purification. All reactions were carried out by standard air-free and moisture-free techniques 
under an inert argon atmosphere with dry solvents unless otherwise stated. Flash column 
chromatography was conducted using Scientific Adsorbents, Inc. silica gel, 60Å, "40 Micron 
Flash" (32-63 µm). Melting points were determined using MEL-TEMP 3.0 apparatus and are 
uncorrected. Routine 1H and 13C NMR spectra were recorded at 300 MHz on a Varian Mercury-
VX spectrometer. All chemical shifts were reported as a part per million (ppm) downfield from 
tetramethylsilane (TMS). All coupling constants (J) are given in Hertz (Hz). Splitting patterns 
are typically described as follows: s, singlet; d, doublet; t, triplet; m, multiplet. ESI/MS was 
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performed on a Waters ZQ 4000 single quadrupole mass spectrometer equipped with an 
electrospray ionization (ESI) LC-MS interface. High performance liquid chromatography 
(HPLC) was performed with an ultraviolet detector operating at 290 nm. Alltech Econosil C18 
250 × 20 mm preparative column and Altech Econosil C18 250 × 4.6 mm analytical column 
were used for purification and analysis respectively.  
Methyl 2-(4-(tert-butoxycarbonylamino)butoxy)-5-iodobenzoate (2) A mixture of 4-(Boc-
amino)butyl bromide (2.50 g, 9.92 mmol), methyl 5-iodosalicylate 1 (3.11 g, 11.19 mmol), and 
potassium carbonate (2.00 g, 14.47 mmol) in acetone (75 mL) was stirred at reflux for 8 h. The 
acetone was evaporated under reduced pressure, then ethyl acetate (100 mL) was added, and the 
mixture was washed with water (50 mL × 2), saturated NaCl (50 mL) and dried over Na2SO4. 
After evaporation of the ethyl acetate under reduced pressure, the crude pruduct was purified by 
flash column chromatography with hexane: ether (1:1) to afford 2.34 g (53%) of 2 as a white 
solid, mp 76.3-76.9 °C. 1H NMR (300 MHz, CDCl3) δ 8.04 (d, J = 1.8 Hz, 1H, Ar-H), 7.67 (dd, 
J = 8.7 Hz, 2.1 Hz, 1H, Ar-H), 6.71 (d, J = 8.7 Hz, 1H, Ar-H), 5.11 (br, 1H, N-H), 4.00 (t, J = 
6.0 Hz, 2H, OCH2), 3.87 (s, 3H, OCH3), 3.19 (m, 2H, NH-CH2), 1.86 (m, 2H, OCH2CH2), 1.71 
(m, 2H, NHCH2CH2), 1.43 (s, 9H, tBu-CH3). 13C NMR (75 MHz, CDCl3) δ 164.8, 158.0, 155.8, 
141.6, 139.6, 121.9, 115.1, 81.3, 78.4, 68.3, 51.8, 39.6, 28.1, 26.3, 25.8.  
Methyl 5-azido-2-(4-(tert-butoxycarbonylamino)butoxy)benzoate (3) A mixture of 2 (900 
mg, 2.0 mmol), sodium azide (390 mg, 6.0 mmol), L-proline (46 mg, 0.4 mmol), NaOH (16 mg, 
0.4 mmol), and CuI (38 mg, 0.2 mmol) in DMSO (12 mL) was heated to 60 °C for 8 h. Ethyl 
acetate (75 mL) was added to the cooled reaction mixture which was washed with water (50 mL 
× 2), saturated NaCl (50 mL), and dried over Na2SO4. After evaporation of the ethyl acetate 
under reduced pressure, the crude pruduct was purified by flash column chromatography with 
dichloromethane: hexane: ether (3:3:1) to afford 714 mg (98%) of 3 as a white solid, mp 58.1-
58.7 °C. 1H NMR (300 MHz, CDCl3) δ 7.47 (d, J = 3.0 Hz, 1H, Ar-H), 7.09 (dd, J = 9.0 Hz, 3.0 
Hz, 1H, Ar-H), 6.94 (d, J = 8.7 Hz, 1H, Ar-H), 4.90 (s, 1H, N-H), 4.03 (t, J = 5.1 Hz, 2H, 
OCH2), 3.89 (s, 3H, OCH3), 3.20 (m, 2H, NH-CH2), 1.87 (m, 2H, OCH2CH2), 1.72 (m, 2H, 
NHCH2CH2), 1.43 (s, 9H, tBu-CH3). 13C NMR (75 MHz, CDCl3) δ 165.6, 156.0, 155.7, 132.1, 
123.7, 121.8, 121.3, 114.7, 78.8, 69.0, 52.0, 39.9, 28.3, 26.6, 26.2.  
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5-Azido-2-(4-(tert-butoxycarbonylamino)butoxy)benzoic acid (4) A mixture of 3 (714 mg, 
1.96 mmol) and lithium hydroxide (56 mg, 2.33 mmol) in methanol (10 mL) and water (2 mL) 
was stirred overnight. The methanol was evaporated under reduced pressure, water (10 mL) was 
added, and impurities were extracted with ethyl acetate (50 mL). The mother liquor was then 
acidified with HCl (1:1) to pH=2, then extracted with ethyl acetate (50 mL); the ethyl acetate 
solution was washed with water (30 mL), saturated NaCl (30 mL), and dried over Na2SO4. After 
evaporation of the ethyl acetate under reduced pressure, the product was dried overnight to 
afford 651 mg (95%) of 4 as a white solid, mp 113.5-114.1 °C. 1H NMR (300 MHz, CDCl3) δ 
7.82 (d, J = 2.7 Hz, 1H, Ar-H), 7.16 (dd, J = 8.9 Hz, 2.7 Hz, 1H, Ar-H), 7.04 (d, J = 8.7 Hz, 1H, 
Ar-H), 4.71 (s, 1H, N-H), 4.25 (t, J = 6.6 Hz, 2H, OCH2), 3.22 (m, 2H, NH-CH2), 1.95 (m, 2H, 
OCH2CH2), 1.69 (m, 2H, NHCH2CH2), 1.44 (s, 9H, tBu-CH3). 13C NMR (75 MHz, CDCl3) δ 
164.9, 154.6, 134.3, 125.3, 123.3, 119.2, 114.4, 79.4, 70.2, 39.3, 28.3, 26.5, 26.1. 
tert-Butyl 4-(4-azido-2-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-
yl)butylcarbamoyl)phenoxy)butylcarbamate (5) Into a solution of 4 (651 mg, 1.86 mmol) and 
4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butan-1-amine (590 mg, 2.23 mmol) in 
dichloromethane (25 mL) was added N,N'-dicyclohexylcarbodiimide (DCC) (575 mg, 2.79 
mmol) and hydroxybenzotriazole (HOBt) (251 mg, 1.86 mmol) at 0 °C. The mixture was stirred 
overnight, then the dichloromethane was evaporated under reduced pressure. Ethyl acetate (75 
mL) was added, and the mixture was washed with saturated NaHCO3 (50 mL), water (50 mL), 
and saturated NaCl (50 mL), then dried over Na2SO4. After evaporation of the ethyl acetate 
under reduced pressure, the crude product was purified by flash column chromatography with 
ethyl acetate: methanol (10:1) to afford 670 mg (60%) of 5 as a white solid, mp 88.1-88.7 °C. 1H 
NMR (300 MHz, CDCl3) δ 8.00 (s, 1H, CON-H), 7.90 (d, J = 3.0 Hz, 1H, Ar-H), 7.02 (dd, J = 
8.7 Hz, 3.0 Hz, 1H, Ar-H), 6.90 (d, J = 8.7 Hz, 1H, Ar-H), 6.58 (s, 1H, Ar-H), 6.49 (s, 1H, Ar-
H), 5.18 (s, 1H, BocN-H), 4.07 (t, J = 6.3 Hz, 2H, OCH2), 3.84 (s, 3H, CH3), 3.83 (s, 3H, CH3), 
3.54 (s, 2H, Ar-CH2N), 3.52 (m, 2H, CONHCH2), 3.09 (m, 2H, BocNHCH2), 2.80 (t, J = 7.2 Hz, 
2H, NCH2), 2.71 (t, J = 5.1 Hz, 2H, Ar-CH2), 2.56 (m, 2H, NCH2), 1.86 (m, 2H, OCH2CH2), 
1.70 (m, 4H, NCH2CH2), 1.62 (m, 2H, NHCH2CH2), 1.44 (s, 9H, tBu-CH3). 13C NMR (75 MHz, 
CDCl3) δ 164.3, 156.1, 156.0, 153.9, 147.4, 147.1, 133.3, 126.4, 126.0, 123.2, 122.8, 122.2, 





acid (WC-21) A solution of 5 (297 mg, 0.5 mmol) in dichloromethane (5 mL) was added 
trifluoroacetic acid (TFA) (5 mL) at 0 °C. The mixture was stirred 3 h at 0 °C. The solvent was 
evaporated under reduced pressure, then triethylamine (TEA) (1 mL) and fluorescein 
thioisocyanate (FITC) (195 mg, 0.5 mmol) were added to a solution of the TFA salt in 
dimethylformamide (10 mL) and the mixture was stirred overnight. Ethyl acetate (100 mL) was 
added, the mixture was washed with water (50 mL x 3), saturated NaCl (50 mL), and dried over 
Na2SO4. After evaporation of the solvent under reduced pressure, the crude product was purified 
with ethyl acetate: methanol (3:1) to afford 211 mg (48%) of WC-21 as an orange solid, which 
was further purified by HPLC, mp 158.1-159.7 °C. LCMS: Calcd for Chemical Formula: 
C47H48N7O9S (M+H), Exact Mass: 886.3, Found: 886.3. 1H NMR (300 MHz, DMSO-d6) δ 10.47 
(s, 1H, COOH), 8.68 (s, 1H, NH), 8.25 (s, 1H, OH), 8.11 (m, 1H, Ar-H), 7.87 (d, J = 2.1 Hz, 1H, 
Ar-H), 7.70 (d, J = 8.4 Hz, 2H, Ar-H), 7.16 (s, 1H, NH), 7.08 (d, J = 8.1 Hz, 1H, Ar-H), 6.95 (d, 
J = 8.4 Hz, 1H, Ar-H), 6.64-6.44 (m, 9H, Ar-H, NH), 4.06 (m, 2H, OCH2), 3.65 (s, 3H, CH3), 
3.63 (s, 3H, CH3), 3.51 (s, 2H, Ar-CH2N), 3.29 (m, 2H, CONHCH2), 2.63 (m, 2H, ArCH2), 2.48 
(m, 4H, NCH2), 2.39 (m, 2H, NCH2), 1.78(m, 2H, OCH2CH2), 1.68 (m, 2H, NCH2CH2), 1.54 (m, 
4H, NCH2CH2). 13C NMR (75 MHz, DMSO-d6) δ 181.1, 169.2, 164.7, 160.4, 154.2, 152.6, 
147.8, 147.5, 142.1, 132.3, 129.6, 127.4, 126.7, 126.3, 125.4, 124.7, 123.0, 121.0, 115.4, 113.3, 
112.3, 110.5, 102.9, 69.4, 57.7, 56.0, 55.5, 51.1, 49.2, 44.0, 28.6, 27.6, 26.7, 25.8, 24.5.  
Preparative HPLC purification of WC-21 
290 nm UV, Preparative column: Alltech Econosil C18 250×20mm,  
Mobile phase: A: 40% Acetonitrile, 60% water, 0.1% TFA 




Analytical HPLC chromatograph of WC-21  
290 nm UV, Analytical column: HPLC-Alltech Econosil C18 250×4.6mm, 10µ,   
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Mobile phase: 60% Acetonitrile, 40% water, 0.1% TFA, 2 ml/min 
 
